Cargando…

Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs

PURPOSE: PEGylated liposomes are important drug carriers that can passively target tumor by enhanced permeability and retention (EPR) effect in neoplasm lesions. This study demonstrated that tumor burden determines the tumor uptake, and also the tumor response, in cancer treatment with PEGylated lip...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yi-Yu, Kao, Hao-Wen, Li, Jia-Je, Hwang, Jeng-Jong, Tseng, Yun-Long, Lin, Wuu-Jyh, Lin, Ming-Hsien, Ting, Gann, Wang, Hsin-Ell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651236/
https://www.ncbi.nlm.nih.gov/pubmed/23675454
http://dx.doi.org/10.1371/journal.pone.0063078
_version_ 1782269187585998848
author Lin, Yi-Yu
Kao, Hao-Wen
Li, Jia-Je
Hwang, Jeng-Jong
Tseng, Yun-Long
Lin, Wuu-Jyh
Lin, Ming-Hsien
Ting, Gann
Wang, Hsin-Ell
author_facet Lin, Yi-Yu
Kao, Hao-Wen
Li, Jia-Je
Hwang, Jeng-Jong
Tseng, Yun-Long
Lin, Wuu-Jyh
Lin, Ming-Hsien
Ting, Gann
Wang, Hsin-Ell
author_sort Lin, Yi-Yu
collection PubMed
description PURPOSE: PEGylated liposomes are important drug carriers that can passively target tumor by enhanced permeability and retention (EPR) effect in neoplasm lesions. This study demonstrated that tumor burden determines the tumor uptake, and also the tumor response, in cancer treatment with PEGylated liposomal drugs in a C26/tk-luc colon carcinoma-bearing mouse model. METHODS: Empty PEGylated liposomes (NanoX) and those encapsulated with VNB (NanoVNB) were labeled with In-111 to obtain InNanoX and InVNBL in high labeling yield and radiochemical purity (all >90%). BALB/c mice bearing either small (58.4±8.0 mm(3)) or large (102.4±22.0 mm(3)) C26/tk-luc tumors in the right dorsal flank were intravenously administered with NanoVNB, InNanoX, InVNBL, or NanoX as a control, every 7 days for 3 times. The therapeutic efficacy was evaluated by body weight loss, tumor growth inhibition (using calipers and bioluminescence imaging) and survival fraction. The scintigraphic imaging of tumor mouse was performed during and after treatment. RESULTS: The biodistribution study of InVNBL revealed a clear inverse correlation (r (2) = 0.9336) between the tumor uptake and the tumor mass ranged from 27.6 to 623.9 mg. All three liposomal drugs showed better therapeutic efficacy in small-tumor mice than in large-tumor mice. Tumor-bearing mice treated with InVNBL (a combination drug) showed the highest tumor growth inhibition rate and survival fraction compared to those treated with NanoVNB (chemodrug only) and InNanoX (radionuclide only). Specific tumor targeting and significantly increased tumor uptake after periodical treatment with InVNBL were evidenced by scintigraphic imaging, especially in mice bearing small tumors. CONCLUSION: The significant differences in the outcomes of cancer treatment and molecular imaging between animals bearing small and large tumors revealed that tumor burden is a critical and discriminative factor in cancer therapy using PEGylated liposomal drugs.
format Online
Article
Text
id pubmed-3651236
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36512362013-05-14 Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs Lin, Yi-Yu Kao, Hao-Wen Li, Jia-Je Hwang, Jeng-Jong Tseng, Yun-Long Lin, Wuu-Jyh Lin, Ming-Hsien Ting, Gann Wang, Hsin-Ell PLoS One Research Article PURPOSE: PEGylated liposomes are important drug carriers that can passively target tumor by enhanced permeability and retention (EPR) effect in neoplasm lesions. This study demonstrated that tumor burden determines the tumor uptake, and also the tumor response, in cancer treatment with PEGylated liposomal drugs in a C26/tk-luc colon carcinoma-bearing mouse model. METHODS: Empty PEGylated liposomes (NanoX) and those encapsulated with VNB (NanoVNB) were labeled with In-111 to obtain InNanoX and InVNBL in high labeling yield and radiochemical purity (all >90%). BALB/c mice bearing either small (58.4±8.0 mm(3)) or large (102.4±22.0 mm(3)) C26/tk-luc tumors in the right dorsal flank were intravenously administered with NanoVNB, InNanoX, InVNBL, or NanoX as a control, every 7 days for 3 times. The therapeutic efficacy was evaluated by body weight loss, tumor growth inhibition (using calipers and bioluminescence imaging) and survival fraction. The scintigraphic imaging of tumor mouse was performed during and after treatment. RESULTS: The biodistribution study of InVNBL revealed a clear inverse correlation (r (2) = 0.9336) between the tumor uptake and the tumor mass ranged from 27.6 to 623.9 mg. All three liposomal drugs showed better therapeutic efficacy in small-tumor mice than in large-tumor mice. Tumor-bearing mice treated with InVNBL (a combination drug) showed the highest tumor growth inhibition rate and survival fraction compared to those treated with NanoVNB (chemodrug only) and InNanoX (radionuclide only). Specific tumor targeting and significantly increased tumor uptake after periodical treatment with InVNBL were evidenced by scintigraphic imaging, especially in mice bearing small tumors. CONCLUSION: The significant differences in the outcomes of cancer treatment and molecular imaging between animals bearing small and large tumors revealed that tumor burden is a critical and discriminative factor in cancer therapy using PEGylated liposomal drugs. Public Library of Science 2013-05-10 /pmc/articles/PMC3651236/ /pubmed/23675454 http://dx.doi.org/10.1371/journal.pone.0063078 Text en © 2013 Lin et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Lin, Yi-Yu
Kao, Hao-Wen
Li, Jia-Je
Hwang, Jeng-Jong
Tseng, Yun-Long
Lin, Wuu-Jyh
Lin, Ming-Hsien
Ting, Gann
Wang, Hsin-Ell
Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs
title Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs
title_full Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs
title_fullStr Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs
title_full_unstemmed Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs
title_short Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs
title_sort tumor burden talks in cancer treatment with pegylated liposomal drugs
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651236/
https://www.ncbi.nlm.nih.gov/pubmed/23675454
http://dx.doi.org/10.1371/journal.pone.0063078
work_keys_str_mv AT linyiyu tumorburdentalksincancertreatmentwithpegylatedliposomaldrugs
AT kaohaowen tumorburdentalksincancertreatmentwithpegylatedliposomaldrugs
AT lijiaje tumorburdentalksincancertreatmentwithpegylatedliposomaldrugs
AT hwangjengjong tumorburdentalksincancertreatmentwithpegylatedliposomaldrugs
AT tsengyunlong tumorburdentalksincancertreatmentwithpegylatedliposomaldrugs
AT linwuujyh tumorburdentalksincancertreatmentwithpegylatedliposomaldrugs
AT linminghsien tumorburdentalksincancertreatmentwithpegylatedliposomaldrugs
AT tinggann tumorburdentalksincancertreatmentwithpegylatedliposomaldrugs
AT wanghsinell tumorburdentalksincancertreatmentwithpegylatedliposomaldrugs